Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA | P42336 | 6/20 | 1.00 |
| ▸ | ABL1 | P00519 | 1/20 | 0.65 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.64 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.58 |
| ▸ | TSHR | P16473 | 1/20 | 0.58 |
| ▸ | CLK1 | P49759 | 3/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.52 |
| ▸ | HTT | P42858 | 2/20 | 0.52 |
| ▸ | POLB | P06746 | 2/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 1/20 | 0.52 |
| ▸ | AHR | P35869 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3137839 | 0.90 | PIK3CA (0.82) | PIK3CAABL1CYP3A4CLK1ALDH1A1 | |
| SCHEMBL3137634 | 0.89 | PIK3CA (1.00) | PIK3CAABL1CYP3A4KDM4ETSHR | |
| SCHEMBL3137796 | 0.85 | PIK3CA (0.75) | PIK3CAABL1CYP3A4TSHRKMT2A | |
| SCHEMBL19808018 | 0.80 | PIK3CA (0.66) | PIK3CACYP3A4KDM4ETSHRCLK1 | |
| SCHEMBL3138028 | 0.80 | PIK3CA (0.84) | PIK3CAABL1CYP3A4CLK1ALDH1A1 | |
| SCHEMBL20855288 | 0.79 | ABL1 (1.00) | PIK3CAABL1CYP3A4KMT2ASMN1; SMN2 | |
| SCHEMBL3131485 | 0.79 | PIK3CA (1.00) | PIK3CAABL1CYP3A4 | |
| SCHEMBL19808002 | 0.79 | PIK3CA (0.65) | PIK3CACYP3A4CLK1 | |
| SCHEMBL11262482 | 0.78 | KDM4E (0.64) | PIK3CAKDM4ETSHRCLK1ALDH1A1 | |
| SCHEMBL11265935 | 0.78 | KDM4E (0.64) | PIK3CAKDM4ETSHRCLK1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100075965-A1 | PI3 KINASE INHIBITORS AND METHODS OF THEIR USE | NOVARTIS AG | 2010-03-25 | — | — | US | disclosed |
| US-20100075965-A1 | PI3 KINASE INHIBITORS AND METHODS OF THEIR USE | NOVARTIS AG | 2010-03-25 | — | — | US | disclosed |
| US-20100075965-A1 | PI3 KINASE INHIBITORS AND METHODS OF THEIR USE | NOVARTIS AG | 2010-03-25 | — | — | US | disclosed |
| WO-2007095588-A1 | PI-3 KINASE INHIBITORS AND METHODS OF THEIR USE | NOVARTIS AG (CH) | 2007-08-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100075965-A1 | PI3 KINASE INHIBITORS AND METHODS OF THEIR USE | PIK3CA, PIK3CD, PIK3CB | PIK3CA 1/4885ABL1 324/4885CYP3A4 4192/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.